7149-82-8

Basic information

• Product Name: 3-(2-Ethylphenoxy)propane-1,2-diol
• Synonyms: 3-(2-Ethylphenoxy)propane-1,2-diol;3-(2-ETHYLPHENOXY)-1,2-PROPANEDIOL
• CAS NO: 7149-82-8
• Molecular Formula: C₁₁H₁₆O₃
• Molecular Weight: 196.2429
• Mol File: 7149-82-8.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 349.3°Cat760mmHg
• Flash Point: 165.1°C
• Appearance: /
• Density: 1.123g/cm³
• Vapor Pressure: 1.77E-05mmHg at 25°C
• Refractive Index: 1.539
• CAS DataBase Reference: 3-(2-Ethylphenoxy)propane-1,2-diol(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(2-Ethylphenoxy)propane-1,2-diol(7149-82-8)
• EPA Substance Registry System: 3-(2-Ethylphenoxy)propane-1,2-diol(7149-82-8)

Safety Data

• Hazardous Substances Data: 7149-82-8(Hazardous Substances Data)

Usage

InChI:InChI=1/C11H16O3/c1-2-9-5-3-4-6-11(9)14-8-10(13)7-12/h3-6,10,12-13H,2,7-8H2,1H3

Upstream product

• 90-00-6 o-Hydroxyethylbenzene 
• 96-24-2 3-monochloro-1,2-propanediol 

Downstream Products

• 1092799-92-2 (S)-3-(2'-ethylphenoxy)-propane-1,2-diol 
• 1092799-94-4 (R)-3-(2'-ethylphenoxy)-propane-1,2-diol 
• 1430052-95-1 1-(2′-ethylphenoxy)-2,3-epoxy-propane 
• 15620-78-7 (R,S)-1-(2′-ethylphenoxy)-2,3-epoxy-propane 
• 1616790-43-2 1-(2′-ethylphenoxy)-2,3-epoxy-propane 
• 174689-39-5 SR 59231A 
• 174689-39-5 (S)-1-(2-Ethyl-phenoxy)-3-[(S)-(1,2,3,4-tetrahydro-naphthalen-1-yl)amino]-propan-2-ol; compound with oxalic acid 
• 174689-39-5 3-(2-ethylphenoxy)-1[(1R)-1,2,3,4-tetrahydronaphth-1-ylamino]-(2S)-2-propanol hydrogen oxalate 
• 174689-39-5 SR 59483A 

Relevant articles and documents

Synthesis of all of the stereoisomers of β3-adrenoceptor antagonist SR 59230 based on the spontaneous resolution of 3-(2-ethylphenoxy)propane-1,2-diol

Racemic 3-(2-ethylphenoxy)propane-1,2-diol 2 has been effectively resolved into (S)- and (R)-enantiomers by a preferential crystallization procedure. Non-racemic diols 2, obtained via a Mitsunobu reaction, have been converted into the non-racemic 1,2-epox

Guaifenesin derivatives promote neurite outgrowth and protect diabetic mice from neuropathy

In diabetic patients, an early index of peripheral neuropathy is the slowing of conduction velocity in large myelinated neurons and a lack of understanding of the basic pathogenic mechanisms hindered therapeutics development. Racemic (R/S)-guaifenesin (1) was identified as a potent enhancer of neurite outgrowth using an in vitro screen. Its R-enantiomer (R)-1 carried the most biological activity, whereas the S-enantiomer (S)-1 was inactive. Focused structural variations to (R/S)-1 was conducted to identify potentially essential groups for the neurite outgrowth activity. In vivo therapeutic studies indicated that both (R/S)-1 and (R)-1 partially prevented motor nerve conduction velocity slowing in a mouse model of type 1 diabetes. In vitro microsomal assays suggested that compounds (R)-1 and (S)-1 are not metabolized rapidly, and PAMPA assay indicated moderate permeability through the membrane. Findings revealed here could lead to the development of novel drugs for diabetic neuropathy.